SCHEMBL2940952

SCHEMBL2940952

CC(C)(C)OC(=O)Nc1ccccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 7/20 0.51
MAPT P10636 5/20 0.51
LMNA P02545 3/20 0.51
HTT P42858 3/20 0.51
HSP90AA1 P07900 1/20 0.49
HSP90AB1 P08238 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
NPC1 O15118 1/20 0.49
TP53 P04637 1/20 0.49
RXFP1 Q9HBX9 1/20 0.48
HPGD P15428 1/20 0.46
BRD9 Q9H8M2 1/20 0.46
METAP1 P53582 1/20 0.45
MEN1 O00255 2/20 0.45
MAPK1 P28482 1/20 0.44
PKM P14618 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2880191 0.89 LMNA (0.54) GAALMNAHTTHSP90AA1HSP90AB1
SCHEMBL5866194 0.85 HSP90AA1 (0.46) LMNAHTTHSP90AA1HSP90AB1POLB
SCHEMBL38661613 0.84 GAA (0.48) GAAMAPTLMNAHTTHSP90AA1
SCHEMBL28697219 0.83 RXFP1 (0.47) GAAMAPTLMNAHTTHSP90AA1
SCHEMBL6241238 0.83 TRPV1 (0.50) GAAHSP90AA1HSP90AB1POLBKMT2A
SCHEMBL10845357 0.83 MAPT (0.47) GAAMAPTLMNAHTTPOLB
SCHEMBL2877719 0.83 GAA (0.49) GAAMAPTLMNAHTTPOLB
SCHEMBL16774987 0.83 GAA (0.52) GAAMAPTLMNAHTTHSP90AA1
SCHEMBL29106089 0.82 CA12 (0.47) LMNAHSP90AA1HSP90AB1POLBRXFP1
SCHEMBL30087033 0.82 HSP90AA1 (0.45) GAAMAPTLMNAHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109485580-A A kind of synthetic method of eltrombopag olamine intermediate 武汉武药科技有限公司 2019-03-19 CN claimed
WO-2016142954-A2 IMPROVED PROCESS FOR THE PREPARATION OF [3R,5R]-2-FLUOROPHENYL-β,δ- DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(2-HYDROXYPHENYLAMINO)- CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID, SODIUM SALT MSN LABORATORIES PRIVATE LIMITED (IN) 2016-09-15 WO claimed
US-20260137698-A1 CYCLIN-DEPENDENT KINASE 7 INHIBITORS JOINT STOCK CO «BIOCAD» (RU) 2026-05-21 US disclosed
CN-122059992-A AKR1C3 selectively activated small molecule drug conjugate and application thereof 中国药科大学 2026-05-19 CN disclosed
CN-122036638-A AKR1C3 inhibitor with tricyclic structure and application thereof 中国药科大学 2026-05-15 CN disclosed
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS LILLY CO ELI (US) 2025-11-20 US disclosed
US-12419976-B2 Hybrid tracers for targeted cancer imaging and treatment ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC) GMBH (NL) 2025-09-23 US disclosed
US-12404298-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2025-09-02 US disclosed
EP-4592283-A1 CYCLIN-DEPENDENT KINASE 7 INHIBITORS Joint Stock Company "Biocad" (RU) 2025-07-30 EP disclosed
WO-2024126533-A1 MULTIPLEXING TARGETING AND IMAGING AGENTS ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) 2024-06-20 WO disclosed
EP-4314005-A1 GLUCOCORTICOID RECEPTOR AGONISTS Eli Lilly and Company (US) 2024-02-07 EP disclosed
WO-2001000565-A1 METHOD FOR PRODUCING ALKOXY ARYLAMINE COMPOUNDS ALLIEDSIGNAL INC. (US) 2001-01-04 WO disclosed
US-6054457-A Benzamide derivatives and their use as vasopressin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-25 US disclosed
CN-1247863-A Carriers for combination of organic synthetic connecting material, their prepn. and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2000-03-22 CN disclosed
EP-0985662-A2 Linker binding carriers for organic synthesis, their production and use Takeda Chemical Industries, Ltd. (JP) 2000-03-15 EP disclosed
EP-0832061-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-04-01 EP disclosed
EP-0595995-B1 ARYLAMIDOALKYL- AND ARYLAMINOALKYL-N-HYDROXYUREA COMPOUNDS AND -N-HYDROXYFORMAMIDE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY ABBOTT LAB (US) 1997-01-15 EP disclosed
WO-1996041795-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-12-27 WO disclosed
US-5514702-A Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory activity ABBOTT LABORATORIES (US) 1996-05-07 US disclosed
US-5214204-A Inhibitors of biosynthesis of leukotrienes ABBOTT LABORATORIES (US) 1993-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12419976-B2 Hybrid tracers for targeted cancer imaging and treatment HNRNPF, ANXA3, SLC67A1 GAA 100/4885MAPT 2016/4885LMNA 1700/4885
US-12404298-B2 Glucocorticoid receptor agonists NR3C1, NR3C2, MC2R GAA 4871/4885MAPT 3892/4885LMNA 4758/4885
US-20260137698-A1 CYCLIN-DEPENDENT KINASE 7 INHIBITORS CDK7, CDK6, CDK3 GAA 2822/4885MAPT 3889/4885LMNA 1547/4885
US-20250353874-A1 GLUCOCORTICOID RECEPTOR AGONISTS NR3C1, NR3C2, MC2R GAA 4871/4885MAPT 3892/4885LMNA 4758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.